Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by stockbuphoonon Jan 19, 2022 9:53pm
158 Views
Post# 34335829

RE:Liminal BioSciences Announces Strategic Priorities For 2022

RE:Liminal BioSciences Announces Strategic Priorities For 2022

Results on 4050 Delayed another quarter - "penicillin" just not cutting it as thomvest creates perception of total failure of 4050 in telegraphed series of press releases. Clearly headed for a financing accomplishing nothing over past year. Who wins? Thomvest again. Silently take over 4050 and sell privately in 3 years under the cover of night. Wait for it.


Dibah420 wrote: More hogwash.

 

<< Previous
Bullboard Posts
Next >>